When everyone plunged in New York Stock Exchange last month, this Shanghai based pharmaceutical company not only raised US$185 million through its initial public offerings (that happened sometime before the lowdown though) but also stood high everyone else had to take their nose dive to down bottom. The numbers crunchers have noticed the pharma company's statistical performance and here we have this macro article on BusinessWeek about Wuxi and on the whole on what scopes companies like these in China are sitting on. 
It says
Industry watchers believe the strong reception for China's leading pharma outsourcing firm is an indication of the country's massive potential in this field.
With the senior staff often Western-trained, these companies offer the lower operational costs of China and an understanding of foreign clients' needs, whether it is meeting quality standards or protecting intellectual property.
To get News, views, analysis, joke, humor, even bitching of outsourcing world Subscribe here
Comment Preview